For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

29th Mar 12

Pharmaxis Announces Agreement for European Supply of Bronchitol

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has finalised a logistics and distribution services agreement for the supply of Bronchitol across Europe. In anticipation of a second quarter commercial launch of Bronchitol for cystic fibrosis in Europe, Pharmaxis has signed a three year agreement with Arvato Healthcare, a member of the Bertelsmann AG group of companies. 

Read full media release - pdf
16th Mar 12

European Regulatory Update on Bronchitol

Pharmaxis is pleased to advise that it has received notification from the European Commission that processing of the Marketing Authorisation application for Bronchitol to treat cystic fibrosis is nearing completion.

The European Commission procedure is expected to conclude next month and Pharmaxis is proceeding with plans for a commercial launch of Bronchitol later in the second quarter in anticipation of a successful outcome. The first commercial launch will be in Germany and the UK, and will be followed by other countries as pricing and reimbursement negotiations are concluded.


Read full media release - pdf
14th Mar 12

Bronchitol to be Reimbursed in Australia

Pharmaceutical company Pharmaxis is pleased to announce that its cystic fibrosis treatment Bronchitol has been recommended for listing on the Pharmaceutical Benefits Scheme (PBS) in Australia by the government’s expert advisory body the Pharmaceutical Benefits Advisory Committee (PBAC).  


Read full media release - pdf